Metabolic

Cagrilintide

Amylin analogue reference material used in appetite-signalling and metabolic research.

Indexed literature

Original citations from PubMed and ClinicalTrials.gov matched to Cagrilintide. Indexing is not a quality endorsement; registration is not a published result.

PubMedResearch publication
Co-agonism of GLP-1R and CTR/AMYR in the lateral dorsal tegmental nucleus produces additive effects on homeostatic and motivated feeding.
Physiology & behavior · 2026 Nov 1
PubMed indexing does not establish study quality or product safety. Read the original publication for methods and limitations.
ClinicalTrials.govRegistered trial — no results posted
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Updated 2026-10-19 · COMPLETED PHASE3
A trial registration is not a published result or proof of safety or effectiveness. Registry information is submitted by study sponsors and investigators.
ClinicalTrials.govRegistered trial — no results posted
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
Updated 2026-10-19 · COMPLETED PHASE3
A trial registration is not a published result or proof of safety or effectiveness. Registry information is submitted by study sponsors and investigators.
ClinicalTrials.govRegistered trial — no results posted
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
Updated 2026-10-19 · RECRUITING PHASE3
A trial registration is not a published result or proof of safety or effectiveness. Registry information is submitted by study sponsors and investigators.
ClinicalTrials.govRegistered trial — no results posted
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
Updated 2026-10-19 · RECRUITING PHASE1
A trial registration is not a published result or proof of safety or effectiveness. Registry information is submitted by study sponsors and investigators.
ClinicalTrials.govRegistered trial — no results posted
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
Updated 2026-10-07 · ACTIVE NOT RECRUITING PHASE3
A trial registration is not a published result or proof of safety or effectiveness. Registry information is submitted by study sponsors and investigators.
PubMedResearch publication
Design and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3).
American heart journal · 2026 Oct 6
PubMed indexing does not establish study quality or product safety. Read the original publication for methods and limitations.
PubMedEvidence review
CagriSema versus Semaglutide 2.4 mg monotherapy for weight management in adults with overweight or obesity, with or without type 2 diabetes: a systematic review, meta-analysis, and trial sequential analysis.
Frontiers in endocrinology · 2026
PubMed indexing does not establish study quality or product safety. Read the original publication for methods and limitations.
PubMedPublished trial
Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1.
Diabetes, obesity & metabolism · 2026 Oct
PubMed indexing does not establish study quality or product safety. Read the original publication for methods and limitations.
PubMedReview
Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs.
Pharmacological research · 2026 Oct
PubMed indexing does not establish study quality or product safety. Read the original publication for methods and limitations.
PubMedEvidence review
Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.
Annals of internal medicine · 2026 Oct
PubMed indexing does not establish study quality or product safety. Read the original publication for methods and limitations.
PubMedReview
Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents.
Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · 2026 Oct
PubMed indexing does not establish study quality or product safety. Read the original publication for methods and limitations.
ClinicalTrials.govRegistered trial — no results posted
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
Updated 2026-09-30 · ACTIVE NOT RECRUITING PHASE3
A trial registration is not a published result or proof of safety or effectiveness. Registry information is submitted by study sponsors and investigators.
ClinicalTrials.govRegistered trial — no results posted
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
Updated 2026-09-30 · COMPLETED PHASE3
A trial registration is not a published result or proof of safety or effectiveness. Registry information is submitted by study sponsors and investigators.
ClinicalTrials.govRegistered trial — no results posted
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
Updated 2026-09-30 · ACTIVE NOT RECRUITING PHASE3
A trial registration is not a published result or proof of safety or effectiveness. Registry information is submitted by study sponsors and investigators.
ClinicalTrials.govRegistered trial — no results posted
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
Updated 2026-09-30 · RECRUITING PHASE3
A trial registration is not a published result or proof of safety or effectiveness. Registry information is submitted by study sponsors and investigators.
ClinicalTrials.govRegistered trial — no results posted
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
Updated 2026-09-30 · RECRUITING PHASE3
A trial registration is not a published result or proof of safety or effectiveness. Registry information is submitted by study sponsors and investigators.
ClinicalTrials.govRegistered trial — no results posted
Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema
Updated 2026-09-30 · RECRUITING PHASE3
A trial registration is not a published result or proof of safety or effectiveness. Registry information is submitted by study sponsors and investigators.
PubMedReview
New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus.
Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026 Sep 28
PubMed indexing does not establish study quality or product safety. Read the original publication for methods and limitations.
ClinicalTrials.govRegistered trial — no results posted
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
Updated 2026-09-24 · COMPLETED PHASE2
A trial registration is not a published result or proof of safety or effectiveness. Registry information is submitted by study sponsors and investigators.
PubMedResearch publication
Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats.
Nature metabolism · 2026 Sep 15
PubMed indexing does not establish study quality or product safety. Read the original publication for methods and limitations.
PubMedResearch publication
Efficacy and Safety of CagriSema for Metabolic Outcomes: Systematic Review and Pairwise Meta-Analysis of Randomized Controlled Trials.
Diabetes, metabolic syndrome and obesity : targets and therapy · 2026
PubMed indexing does not establish study quality or product safety. Read the original publication for methods and limitations.
ClinicalTrials.govRegistered trial — no results posted
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
Updated 2026-09-10 · COMPLETED PHASE2
A trial registration is not a published result or proof of safety or effectiveness. Registry information is submitted by study sponsors and investigators.
ClinicalTrials.govRegistered trial — no results posted
The Role of the Amylin Analogue Cagrilintide in Bone Metabolism
Updated 2026-09-10 · RECRUITING PHASE1
A trial registration is not a published result or proof of safety or effectiveness. Registry information is submitted by study sponsors and investigators.

Materials supplied by Basic Tides are for in-vitro laboratory research only. This page contains no protocols, no dosing information and no therapeutic framing; third-party literature is indexed for reference and is not authored, endorsed or interpreted by Basic Tides.